Juvenile Idiopathic Arthritis

The FDA has approved Tofidence as the first tocilizumab biosimilar in the United States for the treatment of rheumatoid arthritis and other conditions, according to a statement from the manufacturer.

Patients with juvenile idiopathic arthritis who receive baricitinib demonstrate a “significantly” longer time to disease flare vs. placebo, according to data published in The Lancet.

Infants who demonstrate microbiome dysregulation may be at a higher risk for juvenile idiopathic arthritis, according to data published in eBioMedicine.

SAN DIEGO — The recent approvals of belimumab, golimumab, tofacitinib, secukinumab and ustekinumab in children with rheumatic diseases, all within the past 4 years, have changed the landscape in pediatric rheumatology, noted a speaker here.

Knee acoustic emissions may be an “inexpensive and easy-to-use” biomarker to help differentiate between patients with and without juvenile idiopathic arthritis, according to data published in Pediatric Rheumatology.

The overwhelming majority of rheumatology practices have no formal policy for transitioning pediatric patients to adult care, according to a presenter at the 2023 AWIR annual conference.

The field of pediatric rheumatology is at a crossroads.

There is “wide variation” in the way clinicians measure and report the physician’s global assessment of disease activity in patients with juvenile idiopathic arthritis, according to data published in Rheumatology.

Coherus BioSciences’ adalimumab biosimilar, Yusimry, will make its debut in the U.S. marketplace this summer at an 85% discount compared with the originator Humira, according to the manufacturer.

The FDA has given the green light to a new autoinjector option for the interchangeable adalimumab biosimilar Cyltezo, just weeks ahead of its scheduled debut in the United States, according to a press release from the manufacturer.